All In Biotech

Drug Trial Radar · NCT06348303

Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg

A Prospective, Randomized, Single-blind, Pilot Study to Assess Drowsiness, Cognition, and Fall Risk Following Oral Metaxalone 640 mg (M640) Versus Metaxalone 800 mg in Healthy Subjects"

Last checked: Nov 20, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

May 16, 2024

Primary completion

Sep 5, 2024

Study completion Oct 30, 2024

Sponsor

Lead sponsor
Primus PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
ClinOhio Research Services, LLC
First posted
Apr 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Every participant will receive Metaxalone in two (2) stages, one week after the other. A single dose of each Metaxalone dose will be taken one (1) time after a high fat meal which must be eaten within 30 minutes. Every participant will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. Participation in this study will last approximately 2-4 weeks.

Conditions

  • Healthy Participants

Interventions

  • Metaxalone m640 mg oral tabletDrug

    Metaxalone partially micronized 640 mg tablet

  • Metaxalone 800 mg oral tabletDrug

    Metaxalone non-micronized 800 mg oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants unable to maintain Tandem Stand Position for more than 10 seconds (position 3 of the 4-Stage Balance Test).Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)
  2. Change from baseline of gait during a stopwatch timed, stand, and walk activity from a seated position along a 30 foot pathTime frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)
  3. Change from baseline of correct number of steps taken on a fixed 4 inch wide, 9 feet long pathTime frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ClinOhio Research Institute

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.